Hypolipoproteinemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP081 MIFTS: 56	Hypolipoproteinemia Categories: Blood diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Hypolipoproteinemia

MalaCards integrated aliases for Hypolipoproteinemia:

Name: Hypolipoproteinemia ¹¹ ¹⁹ ⁷⁵ ¹⁴

Lipoprotein Deficiencies ¹¹ ⁵³

Hypolipoproteinaemia ¹¹ ³³

Lipoprotein Disorder ⁵³ ⁷¹

Dyslipidaemia, Depressed Hdl Cholesterol ³³

High-Density Lipoprotein Deficiency ³³

Lipoprotein Deficiency Disorder ³³

High-Density Lipoid Deficiency ³³

Lipoprotein Deficiency ³³

Hypolipoproteinemias ⁴³

Hypolipidaemia ³³

Lipoprotein ¹⁶

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Genetic diseases Cancer diseases
Anatomical: Endocrine diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Endocrine, nutritional and metabolic diseases

Metabolic disorders

Disorders of lipoprotein metabolism and other lipidaemias

Lipoprotein deficiency

ICD11: ³³

Endocrine, nutritional or metabolic diseases

Metabolic disorders

Disorders of lipoprotein metabolism or certain specified lipidaemias

Hypolipoproteinaemia

Hypolipoproteinaemia, unspecified

Other specified hypolipoproteinaemia

External Ids:

Disease Ontology ¹¹ DOID:1387

ICD9CM ³⁴ 272.5

MeSH ⁴³ D007009

SNOMED-CT ⁶⁸ 363140000

ICD10 ³¹ E78.6

EFO ¹⁶ EFO_0003836

ICD11 ³³ 526909365 526909365/other 526909365/unspecified

UMLS ⁷¹ C0020623 C0596848

Sources

Summaries for Hypolipoproteinemia

GARD: ¹⁹ Hypolipoproteinemia refers to unusually low levels of fats (lipids) in the blood. Low lipid levels may be caused by rare genetic conditions, or be a sign of another disorder such as overactive thyroid, anemia, undernutrition, cancer, chronic infection, or impaired absorption of foods from the digestive tract. Associated genetic disorders includes abetalipoproteinemia, familial hypobetalipoproteinemia, and chylomicron retention disease. Signs and symptoms in the the genetic or familial form of Hypolipoproteinemia vary. In some forms, although the low density lipoprotein (LDL) cholesterol levels are very low, this syndrome may not cause any symptoms. Other forms result in absent or near absent LDL levels and can cause symptoms in infancy and early childhood.

MalaCards based summary: Hypolipoproteinemia, also known as lipoprotein deficiencies, is related to familial lipoprotein lipase deficiency and lipase deficiency, combined. An important gene associated with Hypolipoproteinemia is ABCA1 (ATP Binding Cassette Subfamily A Member 1), and among its related pathways/superpathways are Metabolism and Transport of inorganic cations/anions and amino acids/oligopeptides. The drugs Liraglutide and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and thyroid, and related phenotypes are Increased free cholesterol and Increased LDL uptake

Disease Ontology: ¹¹ A lipid metabolism disorder that is characterized by unusually low levels of fats in the blood.

Wikipedia: ⁷⁵ Hypolipoproteinemia, hypolipidemia, or hypolipidaemia (British English) is a form of dyslipidemia that... more...

Sources

Related Diseases for Hypolipoproteinemia

Diseases related to Hypolipoproteinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1539)

#	Related Disease	Score	Top Affiliating Genes
1	familial lipoprotein lipase deficiency	32.3	LPL LIPG APOE APOC3 APOB APOA1
2	lipase deficiency, combined	32.2	LPL LIPG
3	abdominal obesity-metabolic syndrome 1	32.1	MTTP MIR33A LPL APOB
4	hypercholesterolemia, familial, 4	32.0	PCSK9 MTTP APOB ABCG5
5	hypercholesterolemia, familial, 2	32.0	APOE APOB
6	fish-eye disease	32.0	LCAT APOA2 APOA1
7	hyperlipoproteinemia, type i	32.0	PCSK9 MTTP LPL LIPG APOE APOC3
8	homozygous familial hypercholesterolemia	32.0	PCSK9 APOB ABCG5
9	hyperlipoproteinemia, type iii	31.9	LPL LPA CETP APOE APOB APOA1
10	apolipoprotein c-iii deficiency	31.8	LPL APOC3
11	hypercholesterolemia, familial, 1	31.8	PCSK9 LPL LPA LCAT CETP APOE
12	hyperlipoproteinemia, type v	31.7	LPL APOE APOC3 APOB APOA1 ANGPTL3
13	arteries, anomalies of	31.7	MIR33A APOE APOB APOA1
14	niemann-pick disease, type c1	31.7	ABCG5 ABCG1 ABCA1
15	hypertriglyceridemia 1	31.7	LPL CETP APOE APOC3 APOB APOA2
16	lecithin:cholesterol acyltransferase deficiency	31.6	LPL LPA LCAT CETP APOE APOB
17	platelet glycoprotein iv deficiency	31.5	SCARB1 LPL APOE APOB
18	lipoprotein quantitative trait locus	31.4	SCARB1 LPL LPA LCAT CETP APOE
19	stroke, ischemic	31.3	LPA APOE APOB ABCA1
20	hyperlipoproteinemia, type iv	31.3	LPL CETP APOE APOC3 APOB APOA1
21	type 1 diabetes mellitus	31.2	LPL APOE APOB APOA1
22	intermediate coronary syndrome	31.2	PCSK9 APOB APOA1
23	hypoalphalipoproteinemia	31.2	LPL LCAT CETP APOC3 APOB APOA2
24	cerebrovascular disease	31.2	LPL CETP APOE APOB APOA1
25	amyloidosis	31.2	LPA APOE APOA2 APOA1
26	arteriosclerosis	31.1	LPA APOE APOB APOA1
27	hyperalphalipoproteinemia 1	31.1	SCARB1 LPL LCAT CETP APOE APOC3
28	aortic valve disease 2	31.1	PCSK9 LPA APOB
29	peripheral artery disease	31.1	PCSK9 APOE APOB
30	prediabetes syndrome	31.1	LPL CETP APOB APOA1
31	chronic kidney disease	31.0	LPL LPA LCAT CETP APOB APOA1
32	vascular disease	31.0	LPL LPA CETP APOE APOB APOA2
33	hypoalphalipoproteinemia, primary, 2	31.0	LPA LCAT CETP APOC3 APOB APOA2
34	nonobstructive coronary artery disease	30.9	APOE APOB APOA1
35	peripheral vascular disease	30.9	LPA LCAT CETP APOE APOB APOA1
36	non-alcoholic steatohepatitis	30.9	SCARB1 MTTP APOB
37	abetalipoproteinemia	30.9	TTPA SAR1B MTTP LPL LCAT CETP
38	heart disease	30.9	PCSK9 LPL LPA CETP APOE APOB
39	uremia	30.8	LPL LCAT APOC3
40	chylomicron retention disease	30.7	SAR1B MTTP APOB
41	kidney disease	30.7	LPA LCAT CETP APOE APOC3 APOB
42	coronary heart disease 1	30.7	PCSK9 MTTP LPL LPA LCAT CETP
43	fatty liver disease	30.7	SCARB1 MTTP LPL APOE APOC3 APOB
44	aortic valve disease 1	30.7	LPA APOE APOB APOA1
45	coronary stenosis	30.6	SCARB1 PCSK9 LPL CETP APOE APOB
46	hypobetalipoproteinemia, familial, 2	30.6	SAR1B PCSK9 MTTP LPL LIPG APOC3
47	hypothyroidism	30.6	PCSK9 LPL LPA CETP APOE APOB
48	xanthomatosis	30.6	LPL LPA APOE APOB ABCA1
49	macular degeneration, age-related, 1	30.6	SCARB1 CETP APOE APOB ABCA1
50	nephrotic syndrome	30.5	PCSK9 LPL LPA LCAT CETP APOE

Graphical network of the top 20 diseases related to Hypolipoproteinemia:

Sources

Symptoms & Phenotypes for Hypolipoproteinemia

GenomeRNAi Phenotypes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased free cholesterol	GR00340-A-2	9.28	APOA1 APOB APOC3 APOE CETP LIPG
2	Increased LDL uptake	GR00340-A-1	8.96	APOA1 APOE

MGI Mouse Phenotypes related to Hypolipoproteinemia:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	liver/biliary system	MP:0005370	9.97	ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOB
2	homeostasis/metabolism	MP:0005376	9.91	ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
3	cardiovascular system	MP:0005385	9.36	ABCA1 ABCG5 APOA1 APOB APOE LCAT

Sources

Drugs & Therapeutics for Hypolipoproteinemia

Drugs for Hypolipoproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Linagliptin

Approved

Phase 4

668270-12-0

57389748 10096344

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Lixisenatide

Approved

Phase 4

320367-13-3

90472060 16139342

Fenofibrate

Approved

Phase 4

49562-28-9

3339

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Methyltestosterone

Approved

Phase 4

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 4

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 4

315-37-7

9416

Testosterone

Approved, Investigational

Phase 4

58-22-0

5408 6013

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184 444254

Probucol

Approved, Investigational

Phase 4

23288-49-5

4912

Orange

Approved

Phase 4

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Simvastatin

Approved

Phase 4

79902-63-9

54454

Glimepiride

Approved

Phase 4

93479-97-1

3476

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Anagliptin

Investigational

Phase 4

739366-20-2

67068474 44513473

Liver Extracts

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Gastrointestinal Agents

Phase 4

Protective Agents

Phase 4

Glucagon-Like Peptide 1

Phase 4

Calcium, Dietary

Phase 4

Antioxidants

Phase 4

Rosuvastatin Calcium

Phase 4

147098-20-2

Phytosterol

Phase 4

Androgens

Phase 4

Testosterone 17 beta-cypionate

Phase 4

Chrysarobin

Phase 4

Cardiac Glycosides

Phase 4

Glycoside Hydrolase Inhibitors

Phase 4

Colesevelam Hydrochloride

Phase 4

Anabolic Agents

Phase 4

Antimetabolites

Phase 4

Hypolipidemic Agents

Phase 4

Anticholesteremic Agents

Phase 4

Lipid Regulating Agents

Phase 4

Vitamins

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B3

Phase 4

Trace Elements

Phase 4

Nicotinic Acids

Phase 4

Vasodilator Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 278)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes	Unknown status	NCT02721888	Phase 4	Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
2	Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients	Unknown status	NCT02280174	Phase 4	linagliptin
3	Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein	Unknown status	NCT00736463	Phase 4	Simvastatin;Atorvastatin 80 mg
4	A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes	Unknown status	NCT02077257	Phase 4	Rosuvastatin
5	Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes	Unknown status	NCT03269058	Phase 4	Dapagliflozin;Placebos
6	The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	Unknown status	NCT02501850	Phase 4	Liraglutide;metformin
7	Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects	Unknown status	NCT01301794	Phase 4
8	Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function	Completed	NCT00298909	Phase 4	niaspan (extended-release niacin);niacin
9	Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration.	Completed	NCT01321034	Phase 4	Niacin/Laropiprant
10	A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study)	Completed	NCT00645151	Phase 4	Atorvastatin
11	Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome	Completed	NCT00841217	Phase 4	GW501516;placebo pill
12	Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome	Completed	NCT00632840	Phase 4	Atorvastatin and fenofibrate
13	Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism	Completed	NCT02111434	Phase 4	Testosterone
14	ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.	Completed	NCT00442325	Phase 4	Atorvastatin (Lipitor)
15	12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients	Completed	NCT00747149	Phase 4	Rosuvastatin
16	ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg	Completed	NCT00442845	Phase 4	Atorvastatin (Lipitor)
17	Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial	Completed	NCT02330406	Phase 4	Anagliptin;Sitagliptin
18	Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients	Completed	NCT02355509	Phase 4	Acarbose;Placebo
19	THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA	Completed	NCT00932620	Phase 4	SIMVASTATIN 40 mg;SIMVASTATIN/EZETIMIBE 10/10 mg
20	Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol	Completed	NCT01122355	Phase 4	lipid modification
21	Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology	Completed	NCT00307307	Phase 4	Niacin/simvastatin compared to simvastatin alone at 2 doses
22	Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy	Completed	NCT00276133	Phase 4	Effects of atorvastatin versus probucol on small dense LDL
23	Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy.	Completed	NCT00249938	Phase 4	Minute Maid Heart Wise orange juice;Welchol
24	The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes	Completed	NCT00931879	Phase 4	omega-3-ethyl esters;Placebo
25	Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups.	Completed	NCT01454011	Phase 4	Testosteron 250mg injection;Testosterone 50mg transdermal application
26	The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes	Completed	NCT01384058	Phase 4	ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20
27	Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes	Completed	NCT02185963	Phase 4	Rosuvastatin
28	Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood	Completed	NCT02839902	Phase 4	TAK-085
29	Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon	Completed	NCT01155206	Phase 4	glucagon
30	Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial	Active, not recruiting	NCT02579499	Phase 4	fixed high potent statin therapy;targeted LDL-C goal statin
31	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes	Terminated	NCT00651014	Phase 4	Ezetimibe;Placebo
32	Effect of Sitagliptin on Postprandial Lipoprotein Metabolism	Terminated	NCT00939939	Phase 4	sitagliptin;glimepiride
33	A Pilot Study Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia in Clinical Routine	Terminated	NCT03559309	Phase 4
34	Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia	Terminated	NCT01239992	Phase 4	Niacin/ Laropiprant
35	An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia	Withdrawn	NCT02069106	Phase 4
36	A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X	Unknown status	NCT01109498	Phase 2, Phase 3	Mycophenolate mofetil;cyclosporine
37	Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)	Unknown status	NCT00633698	Phase 3	Nicotinic acid (niacin);Placebo
38	Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)	Unknown status	NCT01286909	Phase 3
39	ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)	Completed	NCT02658175	Phase 3	Volanesorsen
40	An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects	Completed	NCT00891306	Phase 2, Phase 3	mycophenolate mofetil;cyclosporine;methylprednisolone
41	Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C	Completed	NCT01562080	Phase 2, Phase 3
42	Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like	Completed	NCT01958775	Phase 3	GLP-2;Placebo
43	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes	Completed	NCT00660075	Phase 3	Sitagliptin;Placebo
44	A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment	Completed	NCT02585895	Phase 3
45	A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level.	Completed	NCT02133807	Phase 3
46	A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c)	Completed	NCT00551447	Phase 3	MK0653, ezetimibe / Duration of Treatment: 27 Weeks;MK0733, simvastatin / Duration of Treatment: 27 Weeks;Comparator: simvastatin / Duration of Treatment: 27 Weeks
47	Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity	Completed	NCT00438061	Phase 3
48	Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial	Completed	NCT02116517	Phase 3
49	Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity	Completed	NCT00392717	Phase 3	Atorvastatin;Fish oils
50	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.	Completed	NCT00092638	Phase 3	MK0653, ezetimibe;Comparator: ezetimibe, placebo

Search NIH Clinical Center for Hypolipoproteinemia

Cochrane evidence based reviews: hypolipoproteinemias

Sources

Genetic Tests for Hypolipoproteinemia

Sources

Anatomical Context for Hypolipoproteinemia

Organs/tissues related to Hypolipoproteinemia:

MalaCards : Liver, Heart, Thyroid, Endothelial, Smooth Muscle, Bone Marrow, Skeletal Muscle

Sources

Publications for Hypolipoproteinemia

Articles related to Hypolipoproteinemia:

(show top 50) (show all 30203)

#	Title	Authors	PMID	Year
1	Expression pattern and raft association of NIPSNAP3 and NIPSNAP4, highly homologous proteins encoded by genes in close proximity to the ATP-binding cassette transporter A1. ⁵³ ⁶²	Buechler C...Schmitz G	15177564	2004
2	Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. ⁵³ ⁶²	Pisciotta L...Bertolini S	15019541	2004
3	ATP-binding cassette (ABC) transporters in human metabolism and diseases. ⁵³ ⁶²	Stefkova J...Hubacek JA	15209530	2004
4	Expression, regulation, and activity of ABCA1 in human cell lines. ⁵³ ⁶²	Denis M...Genest J	12706378	2003
5	Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? ⁵³ ⁶²	Durrington PN	11861429	2002
6	Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. ⁵³ ⁶²	Nishida Y...Matsuzawa Y	11785958	2002
7	Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. ⁵³ ⁶²	Lapicka-Bodzioch K...Schmitz G	11476961	2001
8	High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (ABCA1) gene. ⁵³ ⁶²	Iida A...Nakamura Y	11558901	2001
9	Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. ⁵³ ⁶²	Mailly F...Talmud PJ	9401010	1997
10	Suppressive effects of the endothelin receptor (ETA) antagonist BQ-123 on ET-1-induced reduction of lipoprotein lipase activity in 3T3-L1 adipocytes. ⁵³ ⁶²	Ishida F...Yano M	1417963	1992
11	The role of apolipoprotein E genetic variants in lipoprotein disorders. ⁵³ ⁶²	Rall SC...Mahley RW	1619388	1992
12	Low-density lipoprotein encapsulated thiosemicarbazone metal complexes is active targeting vehicle for breast, lung, and prostate cancers. ⁶²	Jaragh-Alhadad L...Karnik S	35815732	2022
13	Myristicin regulates proliferation and apoptosis in oxidized low-density lipoprotein-stimulated human vascular smooth muscle cells and human umbilical vein endothelial cells by regulating the PI3K/Akt/NF-κB signalling pathway. ⁶²	Luo L...Liu L	34905418	2022
14	Serum Lipids and Risk of Incident Psoriasis: A Prospective Cohort Study from the UK Biobank Study and Mendelian Randomization Analysis. ⁶²	Xiao Y...Shen M	35850211	2022
15	Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus. ⁶²	Kurano M...Yatomi Y	35082227	2022
16	Metabolomic profiling for dyslipidemia in pediatric patients with sickle cell disease, on behalf of the IHCC consortium. ⁶²	Qu HQ...Hakonarson H	36459297	2022
17	Two Cases of Acquired High-Density Lipoprotein Deficiency with Immunoglobulin G4-Related Lecithin-Cholesterol Acyltransferase Autoantibody. ⁶²	Komatsu T...Ikewaki K	36384970	2022
18	Association between high oxidized high-density lipoprotein levels and increased pericoronary inflammation determined by coronary computed tomography angiography. ⁶²	Ichikawa K...Ito H	35853799	2022
19	Letter by Lakshmanan et al Regarding Article "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". ⁶²	Lakshmanan S...Nelson JR	36374969	2022
20	Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". ⁶²	Sherratt SCR	36374970	2022
21	Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? ⁶²	Nurmohamed NS...Kastelein JJP	34849601	2022
22	Relationship Between Relative Grip Strength and Serum Total Cholesterol, High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Triglyceride Levels in Korean Middle-Aged or Older Adults: A Panel Regression Model. ⁶²	Park D...Kim Y	36322887	2022
23	High-Density Lipoprotein Suppresses Neutrophil Extracellular Traps Enhanced by Oxidized Low-Density Lipoprotein or Oxidized Phospholipids. ⁶²	Ohinata H...Itabe H	36430470	2022
24	Impact of High-Density Lipoprotein Function, Rather Than High-Density Lipoprotein Cholesterol Level, on Cardiovascular Disease Among Patients With Familial Hypercholesterolemia. ⁶²	Tada H...Kawashiri MA	36436874	2022
25	Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. ⁶²	Zakai NA...Pamir N	36423994	2022
26	Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. ⁶²	Loosen SH...Roderburg C	34897572	2022
27	High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. ⁶²	Trimarco V...Trimarco B	35968698	2022
28	Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting. ⁶²	Kalot G...Sancey L	36149672	2022
29	Neutrophil to high-density lipoprotein ratio associates with higher all-cause mortality and new onset cardiovascular events in peritoneal dialysis patients. ⁶²	Li M...Wen Y	35411415	2022
30	Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. ⁶²	Lacaze P...Tsimikas S	36175048	2022
31	Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study. ⁶²	Bell JA...Davey Smith G	35832062	2022
32	Impact of different training modalities on high-density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. ⁶²	Sowa PW...Adams V	35747946	2022
33	Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. ⁶²	Ishii J...Nagai R	34880156	2022
34	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. ⁶²	Kronenberg F...Catapano AL	36036785	2022
35	High-Density Lipoprotein and Long-Term Incidence and Progression of Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis. ⁶²	Bortnick AE...Kizer JR	35979837	2022
36	The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE-/- mice. ⁶²	Shen Y...Zhang DW	35803528	2022
37	Lipoprotein-X and Lipoprotein-Z Induced Hyperviscosity Syndrome in the Setting of Cholestatic Liver Failure. ⁶²	Waksman O...Rosenson RS	36299645	2022
38	The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. ⁶²	Wen Y...Konrad RJ	35676229	2022
39	Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). ⁶²	Rikhi R...Shapiro MD	36253168	2022
40	The clinical significance of preoperative serum triglyceride, high-density lipoprotein, and low-density lipoprotein levels in lung squamous cell carcinoma. ⁶²	Li Z...Yu G	36207435	2022
41	[Lipoprotein(a) - the unknown lipoprotein]. ⁶²	Parhofer KG	36198968	2022
42	Effect of lipoprotein (a) on the analytical determination of low-density lipoprotein cholesterol (LDLc) and its influence on pharmacological treatment with atorvastatin. ⁶²	Navarro A...Hermida FJ	36200772	2022
43	The association between low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio cholesterol ratio and thickened carotid intima-media thickness: A case-control study. ⁶²	Zhang Z...Hu F	34311590	2022
44	Association between triglyceride-to-high-density lipoprotein cholesterol ratio and prediabetes: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol. ⁶²	Wu L...Wan Q	36273126	2022
45	Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. ⁶²	Glavinovic T...Sniderman AD	36216435	2022
46	Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). ⁶²	O'Donoghue ML...Sabatine MS	35588897	2022
47	Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease: The Japan Epidemiology Collaboration on Occupational Health Study. ⁶²	Hu H...Dohi S	34690212	2022
48	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. ⁶²	Wilson DP...Orringer CE	36068139	2022
49	Association of lipoprotein(a) with aortic dissection. ⁶²	Yang Y...Zheng Z	35925003	2022
50	Possible association of high-density lipoprotein cholesterol levels with trunk muscle deficits and decrease in energy expenditure in patients with or at risk for COPD: A pilot study. ⁶²	Shirahata T...Nakamura H	35821189	2022

Sources

Genes for Hypolipoproteinemia

Genes related to Hypolipoproteinemia (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ABCA1	ATP Binding Cassette Subfamily A Member 1	Protein Coding	27.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15019541 11785958 11476961 (more) 12706378 15177564 11558901 15209530
2	LPL	Lipoprotein Lipase	Protein Coding	21.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9401010 15719845 1417963 (more) 9185775 11122693
3	APOB	Apolipoprotein B	Protein Coding	17.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12545078 11861429
4	LCAT	Lecithin-Cholesterol Acyltransferase	Protein Coding	16.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11122693
5	APOE	Apolipoprotein E	Protein Coding	14.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12535745 1619388
6	APOA1	Apolipoprotein A1	Protein Coding	8.82	DISEASES inferred ¹⁴
7	MTTP	Microsomal Triglyceride Transfer Protein	Protein Coding	8.59	DISEASES inferred ¹⁴
8	MIR33A	MicroRNA 33a	RNA Gene	8.5	DISEASES inferred ¹⁴ ¹⁴
9	ABCG1	ATP Binding Cassette Subfamily G Member 1	Protein Coding	7.96	DISEASES inferred ¹⁴
10	ANGPTL3	Angiopoietin Like 3	Protein Coding	7.65	DISEASES inferred ¹⁴
11	APOA2	Apolipoprotein A2	Protein Coding	7.56	DISEASES inferred ¹⁴
12	SAR1B	Secretion Associated Ras Related GTPase 1B	Protein Coding	7.31	DISEASES inferred ¹⁴
13	CETP	Cholesteryl Ester Transfer Protein	Protein Coding	7.18	DISEASES inferred ¹⁴
14	ABCG5	ATP Binding Cassette Subfamily G Member 5	Protein Coding	7.05	DISEASES inferred ¹⁴
15	PCSK9	Proprotein Convertase Subtilisin/Kexin Type 9	Protein Coding	6.97	DISEASES inferred ¹⁴
16	TTPA	Alpha Tocopherol Transfer Protein	Protein Coding	6.95	DISEASES inferred ¹⁴
17	SCARB1	Scavenger Receptor Class B Member 1	Protein Coding	6.86	DISEASES inferred ¹⁴
18	LPA	Lipoprotein(A)	Protein Coding	6.85	DISEASES inferred ¹⁴
19	APOC3	Apolipoprotein C3	Protein Coding	6.84	DISEASES inferred ¹⁴
20	LIPG	Lipase G, Endothelial Type	Protein Coding	6.82	DISEASES inferred ¹⁴
21	PLTP	Phospholipid Transfer Protein	Protein Coding	6.79	DISEASES inferred ¹⁴
22	APOC2	Apolipoprotein C2	Protein Coding	6.78	DISEASES inferred ¹⁴
23	ABCG8	ATP Binding Cassette Subfamily G Member 8	Protein Coding	6.78	DISEASES inferred ¹⁴
24	ABCA12	ATP Binding Cassette Subfamily A Member 12	Protein Coding	6.46	DISEASES inferred ¹⁴
25	APOA5	Apolipoprotein A5	Protein Coding	6.37	DISEASES inferred ¹⁴
26	ABCG4	ATP Binding Cassette Subfamily G Member 4	Protein Coding	6.32	DISEASES inferred ¹⁴
27	ABCA4	ATP Binding Cassette Subfamily A Member 4	Protein Coding	6.31	DISEASES inferred ¹⁴

Sources

Variations for Hypolipoproteinemia

Sources

Expression for Hypolipoproteinemia

Search GEO for disease gene expression data for Hypolipoproteinemia.

Sources

Pathways for Hypolipoproteinemia

Pathways related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	Metabolism ⁶⁶ Show member pathways Metabolism of lipids ⁶⁶	13.67	TTPA SAR1B LPL APOE APOC3 APOB
2	Transport of inorganic cations/anions and amino acids/oligopeptides ⁶⁶ Show member pathways Amino acid transport across the plasma membrane ⁶⁶ Bicarbonate transporters ⁶⁶ Cation-coupled Chloride cotransporters ⁶⁶ Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN) ⁶⁶ Defective SLC12A1 causes Bartter syndrome 1 (BS1) ⁶⁶ Defective SLC12A3 causes Gitelman syndrome (GS) ⁶⁶ Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) ⁶⁶ Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) ⁶⁶ Defective SLC17A5 causes Salla disease (SD) and ISSD ⁶⁶ Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25) ⁶⁶ Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) ⁶⁶ Defective SLC22A12 causes renal hypouricemia 1 (RHUC1) ⁶⁶ Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) ⁶⁶ Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP) ⁶⁶ Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI) ⁶⁶ Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) ⁶⁶ Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1) ⁶⁶ Defective SLC26A4 causes Pendred syndrome (PDS) ⁶⁶ Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) ⁶⁶ Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) ⁶⁶ Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG) ⁶⁶ Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) ⁶⁶ Defective SLC6A5 causes hyperekplexia 3 (HKPX3) ⁶⁶ Defective SLC9A6 causes X-linked, syndromic mental retardation,, Christianson type (MRXSCH) ⁶⁶ Defective SLC9A9 causes autism 16 (AUTS16) ⁶⁶ Inositol transporters ⁶⁶ Multifunctional anion exchangers ⁶⁶ Na+/Cl- dependent neurotransmitter transporters ⁶⁶ Organic anion transport ⁶⁶ Organic anion transporters ⁶⁶ Organic cation transport ⁶⁶ Organic cation/anion/zwitterion transport ⁶⁶ Proton/oligopeptide cotransporters ⁶⁶ Proton-coupled monocarboxylate transport ⁶⁶ Proton-coupled neutral amino acid transporters ⁶⁶ Rhesus glycoproteins mediate ammonium transport. ⁶⁶ SLC-mediated transmembrane transport ⁶⁶ Sodium/Calcium exchangers ⁶⁶ Sodium/Proton exchangers ⁶⁶ Sodium-coupled phosphate cotransporters ⁶⁶ Sodium-coupled sulphate, di- and tri-carboxylate transporters ⁶⁶ Transport of bile salts and organic acids, metal ions and amine compounds ⁶⁶ Transport of small molecules ⁶⁶ Type II Na+/Pi cotransporters ⁶⁶ Variant SLC6A14 may confer susceptibility towards obesity ⁶⁶	13.34	ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
3	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	12.86	CETP APOE ANGPTL3 ABCG5 ABCG1 ABCA1
4	Metabolism of water-soluble vitamins and cofactors ⁶⁶ Show member pathways Biotin metabolism, including IMDs ⁷⁴ Biotin transport and metabolism ⁶⁶ Coenzyme A biosynthesis ⁶⁶ Defective BTD causes biotidinase deficiency ⁶⁶ Defective HLCS causes multiple carboxylase deficiency ⁶⁶ Defects in biotin (Btn) metabolism ⁶⁶ Metabolism of cofactors ⁶⁶ Metabolism of folate and pterines ⁶⁶ Metabolism of vitamins and cofactors ⁶⁶ molybdenum cofactor biosynthesis ⁶¹ Molybdenum cofactor biosynthesis ⁶⁶ Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation ⁶⁶ thiamin salvage III ⁶¹ Ubiquinol biosynthesis ⁶⁶ Vitamin B1 (thiamin) metabolism ⁶⁶ Vitamin B2 (riboflavin) metabolism ⁶⁶ Vitamin B5 (pantothenate) metabolism ⁶⁶ Vitamin C (ascorbate) metabolism ⁶⁶ Vitamins B6 activation to pyridoxal phosphate ⁶⁶	12.67	TTPA LPL APOE APOC3 APOB APOA2
5	Plasma lipoprotein assembly, remodeling, and clearance ⁶⁶ Show member pathways Assembly of active LPL and LIPC lipase complexes ⁶⁶ Chylomicron assembly ⁶⁶ Chylomicron clearance ⁶⁶ Chylomicron remodeling ⁶⁶ Defective ABCA1 causes TGD ⁶⁶ HDL assembly ⁶⁶ HDL clearance ⁶⁶ HDL remodeling ⁶⁶ LDL clearance ⁶⁶ LDL remodeling ⁶⁶ Metabolic pathway of LDL, HDL and TG, including diseases ⁷⁴ Plasma lipoprotein assembly ⁶⁶ Plasma lipoprotein clearance ⁶⁶ Plasma lipoprotein remodeling ⁶⁶ VLDL assembly ⁶⁶ VLDL clearance ⁶⁶ VLDLR internalisation and degradation ⁶⁶	12.56	ABCA1 ABCG1 ANGPTL3 APOA1 APOA2 APOB
6	Visual phototransduction ⁶⁶ Show member pathways Activation of the phototransduction cascade ⁶⁶ Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D) ⁶⁶ Inactivation, recovery and regulation of the phototransduction cascade ⁶⁶ menaquinol-4 biosynthesis II ⁶¹ Metabolism of fat-soluble vitamins ⁶⁶ Metabolism of vitamin K ⁶⁶ Retinoid metabolism and transport ⁶⁶ retinol biosynthesis ⁶¹ The phototransduction cascade ⁶⁶ The retinoid cycle in cones (daylight vision) ⁶⁶ the visual cycle I (vertebrates) ⁶¹ Visual signal transduction: Rods ⁶¹ Vitamin E ⁶⁶	12.49	TTPA LPL APOE APOC3 APOB APOA2
7	PPARA activates gene expression ⁶⁶ Show member pathways Regulation of lipid metabolism by PPARalpha ⁶⁶ Transcriptional regulation of white adipocyte differentiation ⁶⁶	12.37	LPL APOA2 APOA1 ABCA1
8	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.28	APOA1 APOA2 APOB APOE PCSK9
9	NR1H2 and NR1H3-mediated signaling ⁶⁶ Show member pathways NR1H2 and NR1H3 regulate gene expression linked to gluconeogenesis ⁶⁶ NR1H2 and NR1H3 regulate gene expression linked to lipogenesis ⁶⁶ NR1H2 and NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose ⁶⁶ NR1H2 and NR1H3 regulate gene expression to control bile acid homeostasis ⁶⁶ NR1H2 and NR1H3 regulate gene expression to limit cholesterol uptake ⁶⁶ NR1H3 and NR1H2 regulate gene expression linked to cholesterol transport and efflux ⁶⁶	11.87	CETP APOE ANGPTL3 ABCG5 ABCG1 ABCA1
10	Binding and Uptake of Ligands by Scavenger Receptors ⁶⁶ Show member pathways Scavenging by Class A Receptors ⁶⁶ Scavenging by Class B Receptors ⁶⁶ Scavenging by Class F Receptors ⁶⁶ Scavenging by Class H Receptors ⁶⁶ Scavenging of heme from plasma ⁶⁶	11.75	SCARB1 APOE APOB APOA1
11	PPAR signaling pathway ⁷⁴ Show member pathways FABP4 in ovarian cancer ⁷⁴ Fatty acid transporters ⁷⁴	11.72	LPL APOC3 APOA2 APOA1
12	Statin inhibition of cholesterol production ⁷⁴ Show member pathways Familial hyperlipidemia type 3 ⁷⁴ Lipid particles composition ⁷⁴ Statin Pathway, Pharmacodynamics ⁶⁰	11.65	ABCA1 ABCG5 APOA1 APOA2 APOB APOC3
13	Vitamin A and carotenoid metabolism ⁷⁴	11.34	SCARB1 LPL ABCG5
14	Nuclear receptors in lipid metabolism and toxicity ⁷⁴	11.28	MIR33A ABCG5 ABCG1 ABCA1
15	PPAR-alpha pathway ⁷⁴	11.12	APOC3 APOA2 APOA1
16	Familial hyperlipidemia type 1 ⁷⁴ Show member pathways Familial hyperlipidemia type 2 ⁷⁴ Familial hyperlipidemia type 4 ⁷⁴ Familial hyperlipidemia type 5 ⁷⁴	11.12	ANGPTL3 APOA1 APOA2 APOB CETP LCAT
17	Cholesterol and Sphingolipids transport / Recycling to plasma membrane in lung (normal and CF) ²²	10.95	ABCA1 ABCG1 APOA1 APOA2
18	FOXA2 pathway ⁷⁴	10.88	MTTP APOB
19	Cholestasis ⁷⁴	10.83	SCARB1 ABCG5

Sources

GO Terms for Hypolipoproteinemia

Cellular components related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.56	PCSK9 LPL LPA LIPG LCAT CETP
2	extracellular space	GO:0005615	10.46	ANGPTL3 APOA1 APOA2 APOB APOC3 APOE
3	endoplasmic reticulum lumen	GO:0005788	10.23	APOA1 APOA2 APOB APOE MTTP PCSK9
4	early endosome	GO:0005769	10.16	ANGPTL3 APOA1 APOA2 APOB APOC3 APOE
5	high-density lipoprotein particle	GO:0034364	9.93	LCAT CETP APOE APOB APOA2 APOA1
6	endocytic vesicle lumen	GO:0071682	9.91	APOE APOB APOA1
7	spherical high-density lipoprotein particle	GO:0034366	9.85	APOC3 APOA2 APOA1
8	intermediate-density lipoprotein particle	GO:0034363	9.8	APOE APOC3 APOB
9	very-low-density lipoprotein particle	GO:0034361	9.73	APOA1 APOA2 APOB APOC3 APOE LPL
10	chylomicron	GO:0042627	9.4	LPL APOE APOC3 APOB APOA2 APOA1

Biological processes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show top 50) (show all 60)

#	Name	GO ID	Score	Top Affiliating Genes
1	cholesterol homeostasis	GO:0042632	10.57	ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
2	lipid metabolic process	GO:0006629	10.45	ABCA1 ANGPTL3 APOA1 APOB APOC3 APOE
3	cholesterol metabolic process	GO:0008203	10.43	ABCA1 ABCG1 ANGPTL3 APOA1 APOA2 APOB
4	reverse cholesterol transport	GO:0043691	10.4	ABCA1 ABCG1 APOA1 APOA2 APOC3 APOE
5	triglyceride metabolic process	GO:0006641	10.37	PCSK9 MTTP LPL CETP APOE APOC3
6	phospholipid homeostasis	GO:0055091	10.33	ABCA1 ABCG1 ANGPTL3 APOA1 CETP LIPG
7	lipid transport	GO:0006869	10.33	LPA MTTP SCARB1 ABCA1 ABCG1 ABCG5
8	low-density lipoprotein particle remodeling	GO:0034374	10.31	MTTP CETP APOE APOB APOA2 ABCG1
9	phospholipid efflux	GO:0033700	10.29	ABCA1 ABCG1 APOA1 APOA2 APOC3 APOE
10	high-density lipoprotein particle remodeling	GO:0034375	10.28	APOC3 APOE CETP LCAT LIPG SCARB1
11	very-low-density lipoprotein particle remodeling	GO:0034372	10.27	LPL LCAT CETP APOE APOA1
12	cholesterol transport	GO:0030301	10.27	SCARB1 LCAT CETP APOB APOA2 APOA1
13	phospholipid metabolic process	GO:0006644	10.26	ANGPTL3 APOA1 LCAT LPL PCSK9
14	positive regulation of cholesterol efflux	GO:0010875	10.22	APOE APOA1 ABCG1 ABCA1
15	triglyceride catabolic process	GO:0019433	10.21	LPL LIPG APOC3 APOB
16	lipoprotein biosynthetic process	GO:0042158	10.21	LCAT APOE APOB APOA1 ABCA1
17	high-density lipoprotein particle assembly	GO:0034380	10.2	APOE APOA2 APOA1 ABCA1
18	lipid homeostasis	GO:0055088	10.19	SAR1B CETP APOE ANGPTL3
19	regulation of Cdc42 protein signal transduction	GO:0032489	10.19	APOE APOC3 APOA1 ABCA1
20	high-density lipoprotein particle clearance	GO:0034384	10.19	SCARB1 APOE APOA2 APOA1
21	phospholipid transport	GO:0015914	10.17	SCARB1 MTTP CETP
22	lipid catabolic process	GO:0016042	10.16	APOB APOC3 LIPG LPL
23	artery morphogenesis	GO:0048844	10.15	APOE APOB ANGPTL3
24	phosphatidylcholine biosynthetic process	GO:0006656	10.14	LCAT APOA2 APOA1
25	phosphatidylcholine metabolic process	GO:0046470	10.14	LCAT CETP APOA1
26	phospholipid catabolic process	GO:0009395	10.13	ANGPTL3 APOA2 LIPG
27	lipoprotein transport	GO:0042953	10.13	SAR1B MTTP APOB
28	negative regulation of macrophage derived foam cell differentiation	GO:0010745	10.12	CETP ABCG1 ABCA1
29	steroid metabolic process	GO:0008202	10.12	ABCA1 APOA1 APOB APOE CETP LCAT
30	very-low-density lipoprotein particle assembly	GO:0034379	10.11	MTTP APOC3 APOB
31	positive regulation of CoA-transferase activity	GO:1905920	10.11	APOA1 APOA2 APOE
32	positive regulation of cholesterol storage	GO:0010886	10.1	SCARB1 LPL APOB
33	lipoprotein metabolic process	GO:0042157	10.1	ABCA1 APOA1 APOA2 APOB APOC3 APOE
34	negative regulation of very-low-density lipoprotein particle remodeling	GO:0010903	10.09	APOC3 APOA2 APOA1
35	triglyceride homeostasis	GO:0070328	10.09	ABCG5 ANGPTL3 APOA1 APOC3 APOE CETP
36	negative regulation of low-density lipoprotein particle clearance	GO:0010989	10.03	PCSK9 APOC3
37	negative regulation of cholesterol storage	GO:0010887	10.03	ABCG1 ABCA1
38	cholesterol catabolic process	GO:0006707	10.02	SCARB1 APOE
39	positive regulation of amyloid-beta clearance	GO:1900223	10.02	TTPA APOE
40	positive regulation of lipid catabolic process	GO:0050996	10.02	APOA2 ANGPTL3
41	negative regulation of lipoprotein lipase activity	GO:0051005	10.02	ANGPTL3 APOC3
42	vitamin transport	GO:0051180	10.02	APOA1 TTPA
43	cholesterol import	GO:0070508	10.01	APOA1 SCARB1
44	positive regulation of cholesterol transport	GO:0032376	10.01	LIPG CETP
45	peptidyl-methionine modification	GO:0018206	10.01	APOA2 APOA1
46	negative regulation of cytokine production involved in immune response	GO:0002719	10.01	APOA2 APOA1
47	regulation of intestinal cholesterol absorption	GO:0030300	10	APOA1 APOA2
48	chylomicron remnant clearance	GO:0034382	10	APOC3 APOE
49	lipoprotein catabolic process	GO:0042159	10	APOB APOE
50	positive regulation of cholesterol metabolic process	GO:0090205	9.99	APOA1 APOE

Molecular functions related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 28)

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	10.39	LPL LPA APOE APOA2 APOA1 ANGPTL3
2	heparin binding	GO:0008201	10.27	ANGPTL3 APOB APOE LIPG LPA LPL
3	phospholipid binding	GO:0005543	10.15	APOE APOC3 APOB APOA2 APOA1 ABCG1
4	lipid binding	GO:0008289	10.13	APOA1 APOA2 APOC3 APOE CETP MTTP
5	phosphatidylcholine binding	GO:0031210	10.11	CETP APOA2 APOA1 ABCA1
6	ATPase-coupled transmembrane transporter activity	GO:0042626	10.09	ABCA1 ABCG1 ABCG5
7	low-density lipoprotein particle receptor binding	GO:0050750	10.04	APOB APOE PCSK9
8	phospholipid transporter activity	GO:0005548	10.03	MTTP CETP ABCA1
9	cholesterol binding	GO:0015485	10.03	CETP APOC3 APOA2 APOA1 ABCG1 ABCA1
10	high-density lipoprotein particle binding	GO:0008035	10.01	APOA1 APOA2 SCARB1
11	ABC-type transporter activity	GO:0140359	9.99	ABCG5 ABCG1 ABCA1
12	phosphatidylcholine-sterol O-acyltransferase activator activity	GO:0060228	9.95	APOE APOA2 APOA1
13	phosphatidylserine 1-acylhydrolase activity	GO:0052739	9.94	LPL LIPG
14	lipoprotein lipase activity	GO:0004465	9.93	LPL LIPG
15	1-acyl-2-lysophosphatidylserine acylhydrolase activity	GO:0052740	9.93	LPL LIPG
16	apolipoprotein A-I binding	GO:0034186	9.93	SCARB1 LCAT ABCA1
17	phosphatidylcholine floppase activity	GO:0090554	9.92	ABCG1 ABCA1
18	lipoprotein particle binding	GO:0071813	9.92	LPL APOE APOA1
19	lipase inhibitor activity	GO:0055102	9.91	APOC3 APOA2
20	apolipoprotein receptor binding	GO:0034190	9.91	APOA1 APOA2 PCSK9
21	triglyceride binding	GO:0017129	9.9	LPL CETP
22	floppase activity	GO:0140328	9.88	ABCG1 ABCA1
23	very-low-density lipoprotein particle receptor binding	GO:0070326	9.88	PCSK9 APOE
24	high-density lipoprotein particle receptor binding	GO:0070653	9.88	APOA1 APOA2 APOC3
25	lipid transporter activity	GO:0005319	9.85	MTTP APOE APOB APOA2 APOA1 ABCA1
26	lipid transfer activity	GO:0120013	9.79	TTPA MTTP
27	apolipoprotein binding	GO:0034185	9.73	ABCA1 LPA LPL MTTP PCSK9 SCARB1
28	cholesterol transfer activity	GO:0120020	9.58	MTTP CETP APOE APOB APOA2 APOA1